A5012175543- Immunotherapy and Immune Responses
- Sarcoma Diagnosis and Treatment
- Acute Myeloid Leukemia Research
- T-cell and B-cell Immunology
- Immune Response and Inflammation
- Tumors and Oncological Cases
- Immune Cell Function and Interaction
- Acute Lymphoblastic Leukemia research
- Cancer Genomics and Diagnostics
- Lymphoma Diagnosis and Treatment
- Chronic Myeloid Leukemia Treatments
- Histiocytic Disorders and Treatments
- CAR-T cell therapy research
- Neuroblastoma Research and Treatments
- NF-κB Signaling Pathways
- Pancreatic and Hepatic Oncology Research
- Eosinophilic Disorders and Syndromes
- Renal and related cancers
- Inflammatory Myopathies and Dermatomyositis
- Ocular Oncology and Treatments
- Hemoglobinopathies and Related Disorders
- Virus-based gene therapy research
- Renal and Vascular Pathologies
- Nausea and vomiting management
- Bone Tumor Diagnosis and Treatments
Tokyo National Hospital
2022-2024
National Cancer Center
2020-2024
National Cancer Center Hospital East
2024
Osaka University
2003-2020
RIKEN Center for Integrative Medical Sciences
2003-2020
Osaka International University
2013-2020
Kanagawa Children's Medical Center
2019-2020
Shizuoka Cancer Center
2019
Regenerative Medicine Institute
2017
Toyonaka Municipal Hospital
2015
Stimulation of Toll-like receptors (TLRs) triggers activation a common MyD88-dependent signaling pathway as well MyD88-independent that is unique to TLR3 and TLR4 pathways leading interferon (IFN)-β production. Here we disrupted the gene encoding Toll/IL-1 receptor (TIR) domain-containing adaptor, TRIF. TRIF-deficient mice were defective in both TLR3- TLR4-mediated expression IFN-β IRF-3. Furthermore, inflammatory cytokine production response ligand, but not other TLR ligands, was severely...
Abstract We previously reported a new Toll/IL-1R (TIR)-containing molecule, named TIR domain-containing adaptor inducing IFN-β (TRIF). Although initial study indicated that TRIF possesses the ability to activate not only NF-κB-dependent but also promoters, molecular mechanisms of TRIF-induced signaling are poorly understood. In this study, we investigated cascades through TRIF. TNF receptor-associated factor (TRAF)6 interacted with TRAF domain TRAF6 and TRAF6-binding motifs found in...
Dendritic cells (DCs) consist of various subsets that play crucial roles in linking innate and adaptive immunity. In the murine spleen, CD8α(+) DCs exhibit a propensity to ingest dying/dead cells, produce proinflammatory cytokines, cross-present Ags generate CD8(+) T cell responses. To track ablate vivo, we generated XCR1-venus XCR1-DTRvenus mice, which genes for fluorescent protein, venus, fusion protein consisting diphtheria toxin receptor venus were knocked into gene locus chemokine...
Abstract Intestinal immune homeostasis requires dynamic crosstalk between innate and adaptive cells. Dendritic cells (DCs) exist as multiple phenotypically functionally distinct sub-populations within tissues, where they initiate responses promote homeostasis. In the gut, there exists a minor DC subset defined CD103 + CD11b − that also expresses chemokine receptor XCR1. other XCR1 DCs cross-present antigen contribute to immunity against viruses cancer, however roles of in intestine are...
Identification of genetic alterations through next-generation sequencing (NGS) can guide treatment decision-making by providing information on diagnosis, therapy selection, and prognostic stratification in patients with hematological malignancies. Although the utility NGS-based genomic profiling assays was investigated malignancies, no sufficiently cover driver mutations, including recently discovered ones, as well fusions and/or pathogenic germline variants. To address these issues, here we...
•Of 507 patients who underwent CGP, 12.2% received genomically matched therapies with a 32.3% ORR.•The PFS ratios (>1.3) were observed in 46.3% (19/41) of the evaluated patients.•Patients rare cancers benefited most from tumor mutation profiling.•Early-line treatments following profiling increase therapeutic benefit, irrespective type. BackgroundComprehensive genome (CGP) serves as guide for suitable cancer. However, little is known about impact timing and types cancer on benefit...
Abstract Background Cancer peptide vaccines show only marginal effects against cancers. Immune checkpoint inhibitors (ICIs) significant curative in certain types of cancers, but the response rate is still limited. In this study, we aim to improve cancer vaccination by targeting Ag peptides selectively a dendritic cell (DC) subset, XCR1-expressing DCs (XCR1 + DCs), with high ability support CD8 T-cell responses. Methods We have generated fusion protein, consisting an presented MHC class I,...
Abstract Background Single‐dose i.v. fosaprepitant has been approved as an alternative to 3 day oral aprepitant, a neurokinin‐1 receptor antagonist, and improves prevention of chemotherapy‐induced nausea vomiting ( CINV ). Because shown similar efficacy aprepitant in adult patients only, this study compared the safety pediatric patients. Methods Children younger than 18 years who received or manage between January 2015 March 2018 at National Cancer Center Hospital (Tokyo) were recruited...
Abstract Background The prognosis of relapsed or refractory osteosarcoma remains poor. Recent reports have stated that molecular targeting agents, including multiple tyrosine kinase inhibitors (MTKIs), are effective against adult osteosarcoma. To determine the safety and efficacy MTKI therapy in children, adolescents young adults (AYAs), we conducted a retrospective study on adverse events treatment outcomes. Methods We retrospectively reviewed medical records patients with who received at...
PURPOSE This single-center, prospective molecular profiling study characterizes genomic alterations and identifies therapeutic targets in advanced pediatric solid tumors. METHODS As part of the TOP-GEAR (Trial Onco-Panel for Gene to Estimate both Adverse events Response by cancer treatment) project at National Cancer Center (NCC), Japan, we enrolled patients with a refractory or recurrent disease during August 2016-December 2021 performed analysis matched tumors blood using originally...
ABSTRACT MN1 fusion is emerging as oncogenic in soft‐tissue tumors. Here, we provided detailed clinicopathological documentation of a tumor with :: TAF3 fusion. The developed on the face an 8‐year‐old boy and did not recur or metastasize for 5 years after surgery without adjuvant therapy. Histologically, predominantly comprised sheets nests atypical, mildly pleomorphic epithelioid cells. Mallory body‐like eosinophilic cytoplasmic inclusions, small round cells, fascicles spindle cells were...
There are few treatment options for patients with unresectable or refractory hepatoblastoma which has failed to respond the standard treatment. The rarity of disease and lack experimental materials have hampered development new treatments. In this study, collagen gel droplet-embedded culture drug sensitivity test was used evaluate effectiveness multikinase inhibitors sorafenib sunitinib, other drugs, in relapsed tumor tissues. Tumor samples from 6 were tested by test; evaluable results...
Abstract Philadelphia chromosome (Ph)-like acute lymphoblastic leukemia (ALL) is a subset of ALL that demonstrated high treatment failure rate. One the hallmarks Ph-like PDGFRB gene fusion, with fusion partner proteins often harboring dimerization domains and enhancing kinase activity PDGFRB. We determined novel oncogenic gene, NRIP1::PDGFRB, from pediatric patient ALL, encoding protein carboxy-terminal domain PDGFRB, without peptide. confirmed potential NRIP1::PDGFRB in vitro efficacy all...
Background: Although conservative treatment has been used for unilateral retinoblastoma, enucleation is still the mainstay of ICRB D–E group. In Japan, performed to preserve eyes patients with retinoblastoma including group D–E. We analyzed data treated at our institution aim assessing if therapy in would worsen survival outcomes and it also enable preservation visual acuity. Procedure: retrospectively reviewed medical records from January 1, 2006, December 31, 2015. Survival rates,...